<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>About</td>
<td>03</td>
</tr>
<tr>
<td>Adaption of ASH Clinical Practice Guidelines on Venous</td>
<td>04</td>
</tr>
<tr>
<td>Thromboembolism (VTE) for Latin America</td>
<td></td>
</tr>
<tr>
<td>ASH Clinical Practice Guidelines on the Diagnosis and</td>
<td>05</td>
</tr>
<tr>
<td>Management of Von Willebrand Disease (VWD)</td>
<td></td>
</tr>
<tr>
<td>ASH Awards</td>
<td>06</td>
</tr>
<tr>
<td>Education Initiatives</td>
<td>07</td>
</tr>
<tr>
<td>G10 Coalition</td>
<td>08</td>
</tr>
<tr>
<td>Guidance Initiatives</td>
<td>09</td>
</tr>
<tr>
<td>Highlights of ASH®</td>
<td>10</td>
</tr>
<tr>
<td>Joint Symposia</td>
<td>11</td>
</tr>
<tr>
<td>Lecture Initiatives</td>
<td>12</td>
</tr>
<tr>
<td>Research Initiatives</td>
<td>13</td>
</tr>
<tr>
<td>Sickle Cell Disease Coalition</td>
<td>14</td>
</tr>
<tr>
<td>Training Programs</td>
<td>15</td>
</tr>
<tr>
<td>Additional Initiatives</td>
<td>16</td>
</tr>
<tr>
<td>Contact Us</td>
<td>17</td>
</tr>
</tbody>
</table>
About

With more than 18,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. The Society’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

ASH recognizes that collaboration is fundamental to achieving its mission. By fostering collaboration among hematologists, specialized practitioners, and researchers, ASH appreciates the interconnectedness of scientific innovation, celebrate diversity within both scientific and clinical settings, and catalyze important dialogues.

ASH’s relationship with its partners is a mutually beneficial experience, whereby external organizations can recognize and appreciate the impact and innovation of hematologists across all medical disciplines. In turn, ASH is able to promote research and educational opportunities that benefit all partners.

This overview seeks to highlight the important joint initiatives between ASH and other organizations, both within the U.S. and abroad. We would like to thank all those who have contributed to make these joint initiatives a reality.

*Just as blood is integral to all bodily functions, ASH is integral to facilitating dynamic progress in the fight to treat and eventually cure all hematologic disorders.*
ASH leads and funds a project to adapt the ASH Clinical Practice Guidelines on VTE for Latin America. A panel of regional experts use the evidence gathered for the original Clinical Practice Guidelines on VTE in addition to updated evidence searches and regional searches to adapt the original ASH recommendations in the context of Latin America. Each organization names a representative to the panel, approves the guidelines, and helps with dissemination efforts.
Each of these organizations contributes expertise in Von Willebrand Disease (VWD) and a demonstrated commitment to improving quality of life for patients. By sharing expertise and resources, ASH and the three collaborating organizations are able to ensure high quality, credibility, as well as wide dissemination and implementation of the guidelines once published. ASH leads the project and contributes half of the necessary funding.

**International Society on Thrombosis and Haemostasis (ISTH)**
ISTH advances the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis.

**National Hemophilia Foundation (NHF)**
The National Hemophilia Foundation (NHF) is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.

**World Federation of Hemophilia (WFH)**
WFH is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research.
ASH Awards

ASH Abstract Achievement Awards
ASH partners with other hematological societies to administer the Abstract Achievement Awards. This annual, merit-based award is granted to two to three trainees who are the first or senior author and presenter of the most meritorious country-specific project. The award recognizes awardees on the ASH webpage, in the program book, and in ASH News Daily during the annual meeting.

British Society of Haematology (BSH)  
Japanese Society of Hematology (JSH)

Hematology Society of Australia and New Zealand (HSANZ)  
Society Italiana di Ematologia (SIE)

ASH-AMFDP Award
ASH-Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation
This partnership between ASH and the Robert Wood Johnson Foundation was established to support the ASH Minority Recruitment Initiative (MRI). The award offers four years of postdoctoral research support to historically disadvantaged physicians who are committed to developing careers in academic medicine and to serving as role models for students and faculty of similar backgrounds. The award includes an annual stipend of up to $75,000, an annual grant of $30,000 to support research activities, the support of a National Advisory Committee mentor, complimentary ASH membership, and a stipend to support attendance to both the ASH and AMFDP annual meetings for the four years of the award.
ASH Clinical Research Training Institute (CRTI)
The CRTI is an education and mentoring program. The goal of the program is to produce leaders armed with ideas for clinical hematology research and the tools and resources to make their ideas a reality. International variations of the CRTI program include the ASH CRTI in Latin America, the Advanced ASH CRTI in Latin America, and the ASH CRTI in Asia-Pacific.

Diversity and Inclusion Professionals Networking Group
ASH leads this initiative and partners with multiple societies to facilitate this group. The program fosters opportunities for networking, collaboration, and discussions about best practices across societies and associations. The group holds meetings where featured speakers focus on diversity, equity, and inclusion. ASH is advising the Council of Medical Specialty Societies on the implementation of their diversity and inclusion strategy.

MDS + AML MATTER Program
American Society for Clinical Pathology (ASCP), National Marrow Donor Program (NMDP), and Oncology Nursing Society (ONS)
ASH partners with the ASCP, the NMDP, and the ONS to facilitate this program. This live and enduring education program addresses the many challenges faced by members of the interdisciplinary care team involved in the diagnosis and treatment of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
The G10 is a coalition of ten American Board of Internal Medicine (ABIM) subspecialty societies. All of these societies advocate to reform the Maintenance of Certification (MOC) to ensure that policies and procedures are evidence based, grounded in adult learning theory and are of value to U.S. Board certified physicians.

ASH and the other societies participate in quarterly meetings to identify opportunities where the specialty societies can join forces in advocating for ABIM to reform the MOC.

American Association for the Study of Liver Diseases (AASLD)  
American Geriatrics Society (AGS)

American College of Chest Physicians (ACCP)  
American Society of Nephrology (ASN)

American College of Rheumatology (ACR)  
American Thoracic Society (ATS)

American Gastroenterological Association (AGA/Gastro)  
Endocrine Society

Infectious Diseases Society of America (IDSA)
Federal Programs and Legislative Guidance Policies

Federal Agencies and Congress
ASH regularly collaborates with federal government agencies within the Department of Health and Human Services (HHS) including the National Institutes Of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Centers for Medicare & Medicaid Services (CMS), the Food and Drug Administration (FDA), the Health Resources and Services Administration (HRSA), the Agency for Healthcare Research and Quality (AHRQ), and others. ASH's members offer policy and subject matter expertise to these federal partners. Through these partnerships, ASH seeks to promote issues of importance to hematology research and practice. Additionally, ASH works with various members of Congress to advocate for legislation that impacts hematology research and practice. ASH also works with the Department of Defense (DOD) and the U.S. Department of Veteran Affairs (VA), as well as most White House and Office of the Vice President administrations.

ASTCT Consensus Paper
American Society for Transplantation and Cellular Therapy's (ASTCT) CAR T Therapy Management
ASH collaborates on the development of the ASTCT Consensus Paper. ASH appoints a representative to serve on the ASTCT Consensus writing committee for the guideline document on the management of toxicities resulting from the use of CAR T therapies.

SITC Guidelines
Society for Immunotherapy of Cancer (SITC)
ASH collaborates with the SITC on the development of a guidance document. An ASH-appointed representative sits on the SITC guideline subcommittee. This guideline document covers the management of toxicities resulting from the use of immune effector cell therapies including CAR T.
The Highlights of ASH is an opportunity for hematologists to obtain a synopsis of the top hematology research presented at the latest ASH annual meeting. This meeting is a forum to discuss rapidly evolving developments in hematology and hematology-oncology with leading faculty in the field, discover new treatments for patients, and improve overall practice methods.

Meeting content is tailored to each region and host country. ASH provides speakers and content, and covers the travel expenses for regional hematology societies' trainees to participate in the meeting.

2021 HIGHLIGHTS OF ASH IN ASIA-PACIFIC
Hematology and Blood Transfusion Society of Vietnam
Previous locations include Australia, China, Indonesia, Singapore, and Thailand.

2021 HIGHLIGHTS OF ASH IN LATIN AMERICA
Associação Brasileira de Hematologia, Hemoterapia, e Terapia Celular (ABHH)
Previous locations include Brazil, Chile, Colombia, Peru, and Uruguay.

2021 HIGHLIGHTS OF ASH IN THE MEDITERRANEAN
Turkish Society of Hematology (TSH)
Previous location was Greece.

Due to COVID-19, the 2021 Highlights of ASH Meetings will be presented as a single, virtual event.
ASH partners with other hematologic organizations around the world to promote premier educational and scientific meetings and workshops for hematology professionals worldwide. ASH selects one to two speakers to participate in the following symposia.

**CHINESE SOCIETY OF HEMATOLOGY (CSH)**
September 24-27, 2020
Virtual

**INDIAN SOCIETY OF HEMATOLOGY AND BLOOD TRANSFUSION (ISHBT)**
November 20-22, 2020
Virtual

**JAPANESE SOCIETY OF HEMATOLOGY (JSH)**
October 9-11, 2020
Virtual

**KOREAN SOCIETY OF HEMATOLOGY (KSH)**
April 1-3, 2021
Seoul, South Korea

**EUROPEAN HEMATOLOGY ASSOCIATION (EHA)**
June 10-13, 2021
Vienna, Austria
**Lecture Initiatives**

**ASH Day at AMEH**
*Agrupación Mexicana para el Estudio de la Hematología (AMEH)*
ASH provides up to six speakers and the content for the initiative. Trainees are sponsored to attend the AMEH Annual Meeting to participate in "ASH Day" and Lunch with the Experts just for trainees.

**ASH Special Lecture**
*Japanese Society of Hematology (JSH)*
ASH facilitates a special lecture at the JSH Annual Meeting. The lecture features ASH President Stephanie J. Lee, MD, MPH, who will speak on a topic to be determined.

**Collaboration on Restarting Research**
*Multiple Societies including the American Society of Clinical Oncology (ASCO), National Hemophilia Foundation (NHF), and American Society for Transplantation and Cellular Therapy (ASTCT)*
ASH convenes discussions with ASCO, NHF, ASTCT, and others, regarding the impact of COVID-19 on research, to identify opportunities to collaborate to address gaps and issues. These discussions direct action plans to best support the work of the hematologic research community.

**Joint Session at the International Symposium of the Japanese Society of Hematology**
*Japanese Society of Hematology (JSH)*
ASH partners with JSH for a joint symposium at the International Symposium of the Japanese Society of Hematology. Two ASH members speak alongside two speakers from Japan. They dialogue on topics selected by the JSH Program Committee.
Beat AML
*Leukemia & Lymphoma Society (LLS)*
ASH partners with the Leukemia & Lymphoma Society to raise awareness and provide education about the need for new treatments for acute myeloid leukemia. ASH promotes this to our professional audience and develops an educational webinar with LLS for physicians to increase trial enrollment.

COVID-19 Hem/Onc Fellow Study
*American Society of Clinical Oncology (ASCO)*
ASH developed and administered a study with the American Society of Clinical Oncology (ASCO). This study jointly surveyed all U.S. fellows about COVID-19's impact on their research, educational, and funding needs. The results of the study are currently undergoing analysis.

Curation of Gene Variants Involved in Inherited Hematologic Diseases
*Clinical Genome Resource (ClinGen)*
ASH contributed to this NIH-funded resource to launch two curation panels for essential gene variants in hematologic disorders. One panel focuses on inherited myeloid malignancies and the other panel focuses on inherited platelet disorders.

Practice Profile Study
*American Board of Internal Medicine (ABIM)*
ASH collaborated with the American Board of Internal Medicine to conduct a practice profile study of all hematology board certified physicians. This collaboration includes providing feedback on survey questions during the development process and the collaborating on promotional materials for the survey when it was circulated by ABIM.
The Sickle Cell Disease Coalition (SCDC) is a diverse group of interested organizations that are passionate about improving the lives of individuals with sickle cell disease (SCD). The Coalition was founded because the status quo is unacceptable; we are committed to working together and acting collectively to conquer SCD. We strive to achieve great things for those who unnecessarily suffer from this devastating disease.

- Suzanne Leous, ASH Chief Policy Officer

In 2016, ASH founded the SCDC to help amplify the voice of the SCD stakeholder community, promote awareness, and improve outcomes for individuals with SCD. The SCDC provides members with a platform to communicate with an international network of key stakeholders interested in SCD and engage in joint action.

The SCDC is composed of more than 85 national and global groups representing public health, research, provider organizations, patient groups, federal agencies, industry representatives, and foundations.

The full Coalition meets every other month via webinar. During the alternate months, SCDC working groups connect to discuss access to care, global issues and research, and clinical trials. The Coalition has an annual meeting every September.

Learn more: http://www.scdcoalition.org
Training Programs

**AMEH Board Course Review**
*Agrupación Mexicana para el Estudio de la Hematología (AMEH)*
The Board Course Review is a two-day board preparatory review with three speakers from ASH covering benign and malignant topics selected by AMEH. This program includes Breakfast with the Experts.

**Genomics Essentials in Hematologic Malignancies (GENOM)**
*Leukemia & Lymphoma Society (LLS) and the France Foundation (TFF)*
GENOM is a series of online modules that cover foundational content on genomics followed by disease-specific activities covering major hematologic malignancies and relevant premalignant conditions.

**Scientific Exchange Training Program (SETP)**
*Japanese Society of Hematology (JSH)*
ASH participates in the SETP as a part of the JSH annual meeting. ASH experts including ASH President Stephanie J. Lee, MD, MPH, the joint symposium speakers, and one other ASH member collaborate with eight junior faculty members selected by JSH. The junior faculty present their abstracts and receive feedback on their poster presentation skills from the ASH experts.

**Translational Research Training in Hematology (TRTH)**
*European Hematology Association (EHA)*
TRTH is a joint effort between the American Society of Hematology (ASH) and the European Hematology Association (EHA). This program helps early-career scientists build successful careers in hematologic translational research including pathogenesis, diagnostics, and experimental treatment of hematologic disorders. It provides junior researchers with a unique, year-long training and mentoring experience.
Additional Initiatives

Clinical Trials Navigator Program
*Leukemia and Lymphoma Society (LLS)*
ASH collaborates with LLS’s Clinical Trial Support Center (CTSC) to provide a free, critical, clinical trial resource to blood cancer patients. ASH member physicians and their care teams, along with patients and caregivers, receive one-on-one support from CTSC Nurse Navigators, who provide personal assistance throughout the entire clinical trial process. These Nurse Navigators are specially trained in blood cancers, clinical trials, and patient education and support. ASH member physicians, their care teams, patients, and caregivers have direct access to their CTSC Nurse Navigator for the duration of the search and enrollment process, as well as while patients are on the trials. ASH’s IT team also provides a portal for members to access the program and a video to orient physicians to the process.

**Latin American Registry on Aplastic Anemia (LARAA)**
*Various Partner Societies in Latin America*
ASH has created a “Proof of Concept” registry across Latin America, establish common standards, and allow participants to retain ownership of data. A three-year retrospective study comprises the first phase of the initiative and provides baseline data on the distribution of aplastic anemia and its specific characteristics in the region.

**Health Volunteers Overseas (HVO)**
This program reflects a long-standing partnership with HVO, in which ASH member volunteers help build capacity in low- and middle-income countries, including Cambodia, Peru, Tanzania, and Uganda. ASH volunteers provide targeted training and lectures.
Questions?

E-mail Angela Georgopoulos, Director of Business Development, at:

ageorge@hematology.org